
Before the end of the year, Evaxion will begin its phase IIb trial of its lead candidate EVX-01 against metastatic melanoma in a partnership with US-based MSD.
The Danish biotech company reported the news in a press release stating its objective to test its drug in combination with Keytruda, which MSD will provide free of charge for the trial.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app